Previous studies showed that fulvestrant inhibited the proliferation of HepG2 cell, via the ERα and non-canonical Wnt pathways, and indicated that it may be a promising therapeutic for HCC (Wang et al., 2014). The gene discussed is ESR1; the disease is hepatocellular carcinoma.